The KEYNOTE-012 results of a multicenter, open label, phase 1b clinical trial conducted by Muro et al. indicated that Pembrolizumab had controllable toxicity and good anti-tumor activity in PD-L1-positive patients with advanced GC [14]. The gene discussed is CD274; the disease is neoplasm.